i would like to ask you , what kind of a Dr. prescribed this medication? have you got a second opinion? A PEDIATRICIAN? NOT A PSYCHIATRIST, NOT A SCHOOL RECOMMENDATION?ARE THEY STARTING ON THE LOWEST POSSIBLE DOSE? what kind of things are going on, that are THAT severe, that they would consider medicaiton. are the behaviors interfering with their life? and in what way? at home? at school? friends? i think you are doing the right thing by asking questions, BUT ASK MORE, LOOK DEEPER, really look deeper,
look for answers to questions such as, WHAT IS GOING TO HAPPEN WHEN THEY START TO TAKE IT?
WHAT HAPPENS WHEN WE TAKE THEM OFF? DO YOU HAVE TO WEAN THEM OFF? IS IT ADDICTING? WHAT KIND OF WITHDRAWL WILL HAPPEN TO MY CHILD AFTER HE QUITS TAKING IT? IS IT ONE OF THOSE MEDICATIONS, THAT HAS PHYSICAL SIDE EFFECTS? , BUT HERE IS WHAT ONE TRIAL I READ SAID,
SEE IF YOU CAN GO TO PUBMEDED AND LOOK UP TRIALS, HERE IS WHAT ONE SAID, Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy. case of hyponatremia in a patient that occurred 3 days after initiation of treatment with aripiprazole. We caution clinicians to be aware that the potential hyponatremic-inducing effects of atypical antipsychotics can occur rapidly after initiation of the medications ABOUT WHAT CAN HAPPEN WHEN TAKING AMBILIFY, Tardive dyskinesia (TD) is usually a late-developing, well-known neuromuscular adverse effect associated with the long-term use of first-generation (typical or conventional) anti-psychotic agents, such as chlorpromazine (Thorazine, Glaxo-SmithKline), haloperidol (Haldol, Ortho-McNeil), and fluphenazine (Prolixin, Apothecon). After months to years of therapy with dopamine-2 (D2) receptor–blockers, patients often experience involuntary choreiform, athetotic, or ballismic dyskinetic movements. These movements most commonly involve the mouth, tongue, facial muscles, and upper extremities. Axial dyskinesias may also occur.Typical risk factors associated with the development of TD include older age, pre-existing movement or neurodegenerative disorders, female sex, the presence of affective illness, and neuroleptic exposure of more than six months.Another patient who was developmentally disabled with obsessive-compulsive disorder was treated with aripiprazole 10 mg. This patient experienced an acute dystonic face, tongue, and arm movements as well as upper limb athetosis. These acute dystonic events were alleviated with diphenhydramine (Benadryl, Pfizer).15 With their ability to reduce the risk of EPS, the atypical antipsychotic agents are the current drugs of choice for schizophrenia and bipolar illness as well as for many off-label applications. Almost all available SGAs have been linked to cases of TD, and a larger naturalistic evidence base is developing as patient exposures increase over time. Therefore, we need to continuously monitor individuals treated with antipsychotic medications regardless of their dose, diagnosis, or choice of SGAs over the conventional antipsychotic drugs. THERE ARE PROBABLY ALOT MORE,